Arranz Martín Alfonso, Lecumberri Pascual Edurne, Brito Sanfiel Miguel Ángel, Andía Melero Víctor, Nattero Chavez Lia, Sánchez López Iván, Cánovas Molina Gloria, Arrieta Blanco Francisco, González Perez Del Villar Noemí
Servicio de Endocrinología y Nutrición, Hospital Universitario de la Princesa, Madrid, España.
Servicio de Endocrinología y Nutrición, Hospital Universitario Fundación Jiménez Díaz, Madrid, España.
Endocrinol Diabetes Nutr. 2017 Jan;64(1):34-39. doi: 10.1016/j.endinu.2016.09.001. Epub 2017 Jan 19.
To report the clinical characteristics of patients with latent autoimmune diabetes in adults (LADA), and to ascertain their metabolic control and associated chronic complications.
Patients with DM attending specialized medical care in Madrid who met the following criteria: age at diagnosis of DM >30years, initial insulin independence for at least 6months and positive GAD antibodies were enrolled. Clinical profiles, data on LADA diagnosis, associated autoimmunity, C-peptide levels, therapeutic regimen, metabolic control, and presence of chronic complications were analyzed.
Number of patients; 193; 56% females. Family history of DM: 62%. Age at DM diagnosis: 49years. Delay in confirmation of LADA: 3.5years. Insulin-independence time: 12months. Baseline serum C-peptide levels: 0.66ng/ml. Basal-bolus regimen: 76.7%. Total daily dose: 35.1U/day, corresponding to 0.51U/Kg. With no associated oral antidiabetic drugs: 33.5%. Other autoimmune diseases: 57%. Fasting plasma glucose: 160.5mg/dL. HbA1c: 7.7%. BMI: 25.4kg/m (overweight, 31.5%; obesity, 8%). Blood pressure: 128/75. HDL cholesterol: 65mg/dL. LDL cholesterol: 96mg/dL. Triglycerides: 89mg/dL. Known chronic complications: 28%.
Recognition of LADA may be delayed by several years. There is a heterogeneous pancreatic insulin reserve which is negative related to glycemic parameters. Most patients are poorly controlled despite intensive insulin therapy. They often have overweight, but have adequate control of BP and lipid profile and a low incidence of macrovascular complications.
报告成人隐匿性自身免疫性糖尿病(LADA)患者的临床特征,并确定其代谢控制情况及相关慢性并发症。
纳入在马德里接受专科医疗护理且符合以下标准的糖尿病患者:糖尿病诊断时年龄>30岁、初始至少6个月无需胰岛素治疗且谷氨酸脱羧酶抗体阳性。分析临床资料、LADA诊断数据、相关自身免疫情况、C肽水平、治疗方案、代谢控制情况以及慢性并发症的存在情况。
患者数量为193例;女性占56%。糖尿病家族史:62%。糖尿病诊断时年龄:49岁。LADA确诊延迟时间:3.5年。无需胰岛素治疗时间:12个月。基线血清C肽水平:0.66ng/ml。基础-餐时胰岛素治疗方案:76.7%。每日总剂量:35.1U/天,相当于0.51U/kg。未联合使用口服降糖药:33.5%。其他自身免疫性疾病:57%。空腹血糖:160.5mg/dL。糖化血红蛋白:7.7%。体重指数:25.4kg/m²(超重,31.5%;肥胖,8%)。血压:128/75。高密度脂蛋白胆固醇:65mg/dL。低密度脂蛋白胆固醇:96mg/dL。甘油三酯:89mg/dL。已知慢性并发症:28%。
LADA的识别可能会延迟数年。胰腺胰岛素储备存在异质性,且与血糖参数呈负相关。尽管进行了强化胰岛素治疗,但大多数患者控制不佳。他们常超重,但血压和血脂控制良好,大血管并发症发生率低。